Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines
- PMID: 11156257
Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines
Abstract
We studied the effect of arsenic trioxide (As2O3) on prostate and ovarian carcinoma cell lines. As2O3 has been shown to be effective in leukemia, and acute promyelocytic leukemia in particular, both in vitro and in vivo. As model cell lines, we used DU145 and PC-3 for prostate cancer and MDAH 2774 for ovarian cancer. New modalities of treatment are essential in these kinds of cancers, which produce a high death toll. The 3-(4,5-dimethyl-thiazoyl-2-yl)-2,5-diphenyl-tetrazolium bromide assay was used to evaluate cytotoxicity. Flow cytometric analysis and mono-oligo nucleosome detection-based ELISA were used to determine the apoptosis. Isobologram analysis was used to evaluate synergism and/or the additive effects of As2O3 and conventional chemotherapeutic agents. We clearly demonstrated that As2O3 has significant cytotoxic effect on both prostate and ovarian carcinoma cell lines. The dose range of As2O3 in all three cell lines was approximately 10(-6) M. The mechanism underlying cytotoxicity of As2O3 was shown to be apoptosis. The experiments by butylated hydroxyanisole showed that the cytotoxic effect of As2O3 was not through superoxide generation. There was no synergism, but the additive effects of As2O3 were demonstrated with cisplatin, adriamycin, and etoposide. We strongly suggest that As2O3 alone or in combination with conventional chemotherapeutic agents be evaluated further as a new agent for the treatment of prostate and ovarian cancers.
Similar articles
-
Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines.Cancer Chemother Pharmacol. 2001 Jun;47(6):481-90. doi: 10.1007/s002800100278. Cancer Chemother Pharmacol. 2001. PMID: 11459200
-
Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.Cancer Res. 2001 Jul 15;61(14):5432-40. Cancer Res. 2001. PMID: 11454688
-
Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.Int J Oncol. 2004 Jun;24(6):1489-97. Int J Oncol. 2004. PMID: 15138592
-
The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages.Leuk Lymphoma. 2000 Jun;38(1-2):153-63. doi: 10.3109/10428190009060329. Leuk Lymphoma. 2000. PMID: 10811458 Review.
-
The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.J Biol Regul Homeost Agents. 1999 Oct-Dec;13(4):195-200. J Biol Regul Homeost Agents. 1999. PMID: 10703942 Review.
Cited by
-
Research progress on arsenic, arsenic-containing medicinal materials, and arsenic-containing preparations: clinical application, pharmacological effects, and toxicity.Front Pharmacol. 2024 Mar 1;15:1338725. doi: 10.3389/fphar.2024.1338725. eCollection 2024. Front Pharmacol. 2024. PMID: 38495096 Free PMC article. Review.
-
Application of Arsenic Trioxide-Based Combined Sequential Chemotherapy in Recurrent Resistant and Refractory Ovarian Cancers: A Single-Center, Open Phase II Clinical Study.J Oncol. 2022 Aug 31;2022:6243165. doi: 10.1155/2022/6243165. eCollection 2022. J Oncol. 2022. PMID: 36090905 Free PMC article.
-
Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes.J Cell Mol Med. 2022 May;26(9):2728-2740. doi: 10.1111/jcmm.17286. Epub 2022 Apr 2. J Cell Mol Med. 2022. PMID: 35366048 Free PMC article.
-
Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy.Drug Des Devel Ther. 2021 Jan 6;15:9-20. doi: 10.2147/DDDT.S285852. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 33442233 Free PMC article. Review.
-
Role of Reactive Oxygen Species in the Cytotoxicity of Arsenic Trioxide and Pamidronate for Human Prostate Cancer Cells.React Oxyg Species (Apex). 2020 Mar;9(26):81-94. React Oxyg Species (Apex). 2020. PMID: 32337366 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials